EICHORCondition: Advanced Solid Tumor · Ovarian Cancer · Ovarian Clear Cell Carcinoma · Sponsor: Nuvectis Pharma, Inc.
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Honor Health | Phoenix, Arizona, United States | — |
| UC San Diego Health - Moores Cancer Center | La Jolla, California, United States | — |
| University of Colorado Cancer Center | Aurora, Colorado, United States | — |
| Yale Gynecologic Oncology | New Haven, Connecticut, United States | — |
| Florida Cancer Specialists South | Fort Myers, Florida, United States | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | — |
| Florida Cancer Specialists Research North | St. Petersburg, Florida, United States | — |
| Florida Cancer Specialists Research East | West Palm Beach, Florida, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | — |
| Women's Cancer Care Associates | Albany, New York, United States | — |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05226507